Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors

被引：0
|
作者：
Abou Jokh Casas, E. [1 ]
Pombo Pasin, M. D. [1 ]
Pubul Nunez, V. [1 ]
Garrido Pumar, M. [1 ]
Blanco Freire, M. N. [1 ]
Cabezas, J. [1 ]
Cameselle, J. [1 ]
Berrios, M. [1 ]
Argibay, S. [1 ]
Ruibal Morell, A. [1 ]
机构：
[1] Complejo Hosp Univ Santiago de Compostela, Santiago De Compostela, Spain
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0742
引用
收藏
页码：S597 / S598
页数：2
相关论文
共 50 条
  • [41] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177Lu) Is Effective and Safe in Patients with Pretreated Metastatic Neuroendocrine Tumors: Data from Spanish SEPTRALU Registry
    Bello, P.
    Jimenez-Fonseca, P.
    Percovich, J. C.
    Anido Herranz, U.
    Gajate, P.
    Castellon, M.
    Estorch, M.
    Gonzalez, E.
    Field, C.
    Garcia Alonso, P.
    Carmona-Bayonas, A.
    Mitjavila, M.
    NEUROENDOCRINOLOGY, 2019, 108 : 198 - 198
  • [42] Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with 177Lu-DOTATATE
    Parghane, Rahul V.
    Basu, Sandip
    JOURNAL OF NUCLEAR CARDIOLOGY, 2020, 27 (01) : 340 - 341
  • [43] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
    Zandee, Wouter T.
    Brabander, Tessa
    Blazevic, Anela
    Minczeles, Noemie S.
    Feelders, Richard A.
    de Herder, Wouter W.
    Hofland, Johannes
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : E3665 - E3672
  • [44] Towards a quality assurance for dosimetry in peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE
    Marin, G.
    Vanderlinden, B.
    Wimana, Z.
    Guiot, T.
    Karfis, I.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S159 - S160
  • [45] Safety and response after peptide receptor radionuclide therapy with 177Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial
    Kudo, Atsushi
    Tateishi, Ukihide
    Yoshimura, Ryoichi
    Tsuchiya, Junichi
    Yokoyama, Kota
    Takano, Shoko
    Kobayashi, Noritoshi
    Utsunomiya, Daisuke
    Hata, Masaharu
    Ichikawa, Yasushi
    Tanabe, Minoru
    Hosono, Makoto
    Kinuya, Seigo
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2022, 29 (04) : 487 - 499
  • [46] 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis
    Satapathy, Swayamjeet
    Mittal, Bhagwant Rai
    NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (12) : 1195 - 1203
  • [47] Combined use of 177Lu-DOTATATE peptide receptor radionuclide therapy and fluzoparib for treatment of well-differentiated neuroendocrine tumors: A preclinical study
    Fu, Jingjing
    Qiu, Fan
    Stolniceanu, Cati Raluca
    Yu, Fei
    Zang, Shiming
    Xiang, Yili
    Huang, Yue
    Matovic, Milovan
    Stefanescu, Cipriana
    Tang, Qiyun
    Wang, Feng
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 (04)
  • [48] 177Lu-DOTATATE Retention and Radiation Protection Precautions for Patients Undergoing Inpatient and Outpatient Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumours
    Levart, D. L.
    Kalogianni, E.
    Corcoran, B.
    Mulholland, N.
    Vivian, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S732 - S733
  • [49] Comparison of commercial dosimetric software platforms in patients treated with 177Lu-DOTATATE for peptide receptor radionuclide therapy
    Mora-Ramirez, Erick
    Santoro, Lore
    Cassol, Emmanuelle
    Ocampo-Ramos, Juan C.
    Clayton, Naomi
    Kayal, Gunjan
    Chouaf, Soufiane
    Trauchessec, Dorian
    Pouget, Jean-Pierre
    Kotzki, Pierre-Olivier
    Deshayes, Emmanuel
    Bardies, Manuel
    MEDICAL PHYSICS, 2020, 47 (09) : 4602 - 4615
  • [50] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Yeokyeong Shin
    Bo Hyun Moon
    Baek-Yeol Ryoo
    Heung-Moon Chang
    Kyu-pyo Kim
    Yong Sang Hong
    Tae Won Kim
    Jin-Sook Ryu
    Yong-il Kim
    Changhoon Yoo
    Targeted Oncology, 2024, 19 : 41 - 49
12345